# The Role of Elafin in the Pathogenesis of Psoriasis

## TL;DR

This study found that psoriasis patients have higher levels of a protein called elafin, which may be linked to the severity of the disease.

## Contribution

The study identifies elafin as a potential biomarker for psoriasis severity.

## Key findings

- Psoriasis patients had significantly higher serum elafin levels than healthy controls.
- Elafin levels were positively correlated with PASI scores, indicating disease severity.

## Abstract

Psoriasis is a chronic, immune-mediated inflammatory disease that affects the skin, nails, joints, and cardiovascular system. In this study, involving 50 psoriatic patients and 28 healthy controls (patients with inguinal hernia), serum elafin levels were measured using enzyme-linked immunosorbent assay (ELISA). The results revealed significantly higher serum elafin levels in the psoriatic group compared to healthy individuals. Moreover, we observed a statistically significant positive correlation between serum elafin levels and the Psoriasis Area and Severity Index (PASI) scores. These findings indicate that elafin—a protein involved in psoriasis pathogenesis—is significantly altered in the serum of psoriatic patients and may be associated with disease severity.